Print Page  Close Window


SEC Filings

S-1/A
OREXIGEN THERAPEUTICS, INC. filed this Form S-1/A on 02/16/2007
Entire Document
 
Table of Contents

As noted, weight loss at 24 weeks was the primary endpoint for this trial. However, the protocol permitted study participants to continue on Contrave or bupropion for an additional 24 week period. The study is ongoing and 48 week data is not yet available. Data through 36 weeks of treatment indicates that subjects, on average, continued to lose weight in the interval from weeks 24 to 36. For the intent-to-treat and completer populations, the results were as follows:
 
Contrave Phase IIb Mean Weight Loss at 36 Weeks
Intent-to-Treat Population
 
(GRAPH)
 
* Calculated on the basis of unadjusted least-squares mean methodology.
 
Contrave Phase IIb Mean Weight Loss at 36 Weeks
Completer Population
 
(GRAPH)
 
* Calculated on the basis of unadjusted least-squares mean methodology.


67